DK1534707T5 - Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer - Google Patents

Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer

Info

Publication number
DK1534707T5
DK1534707T5 DK03761110T DK03761110T DK1534707T5 DK 1534707 T5 DK1534707 T5 DK 1534707T5 DK 03761110 T DK03761110 T DK 03761110T DK 03761110 T DK03761110 T DK 03761110T DK 1534707 T5 DK1534707 T5 DK 1534707T5
Authority
DK
Denmark
Prior art keywords
dihydropyrrolo
quinolin
substituted
phosphodiesterase inhibitors
derivatives useful
Prior art date
Application number
DK03761110T
Other languages
Danish (da)
English (en)
Other versions
DK1534707T3 (da
Inventor
Weiqin Jiang
Zhihua Sui
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of DK1534707T3 publication Critical patent/DK1534707T3/da
Application granted granted Critical
Publication of DK1534707T5 publication Critical patent/DK1534707T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK03761110T 2002-06-19 2003-06-17 Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer DK1534707T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38990402P 2002-06-19 2002-06-19
PCT/US2003/019262 WO2004000842A1 (fr) 2002-06-19 2003-06-17 Derives substitues de 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one utilises comme inhibiteurs de la phosphodiesterase

Publications (2)

Publication Number Publication Date
DK1534707T3 DK1534707T3 (da) 2008-03-25
DK1534707T5 true DK1534707T5 (da) 2010-01-11

Family

ID=30000482

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03761110T DK1534707T5 (da) 2002-06-19 2003-06-17 Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer

Country Status (13)

Country Link
US (1) US6800625B2 (fr)
EP (1) EP1534707B9 (fr)
JP (1) JP4916662B2 (fr)
CN (1) CN100349893C (fr)
AU (2) AU2003243640A1 (fr)
CA (1) CA2490239C (fr)
CY (1) CY1107196T1 (fr)
DE (2) DE60317684D1 (fr)
DK (1) DK1534707T5 (fr)
ES (1) ES2297217T3 (fr)
PT (1) PT1534707E (fr)
SI (1) SI1534707T1 (fr)
WO (1) WO2004000842A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (fr) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Composés de succinimide hétérocyclique fondu et leurs analogies, modulateurs de la fonction de récepteur d'hormone nucléaire
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
DE102004017435A1 (de) * 2004-04-08 2005-11-03 Bayer Cropscience Ag Annellierte Chinolinderivate
WO2006070385A1 (fr) * 2004-12-27 2006-07-06 Council Of Scientific And Industrial Research Esters/amides de l'acide 2-alkyl- ou 2-arylsulfonyl-1,2,3,4-tétrahydro-9h-pyrido(3,4-b)indole-3-carboxylique employés en tant qu'agents antithrombotiques
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
RU2569899C1 (ru) * 2014-12-16 2015-12-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" Способ получения 6-арил-2-(2-гидроксифенил)-7,15-диокса-2-азатетрацикло[6.5.2.01,5.08,13]пентадец-5-ен-3,4,14-трионов

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2023514A1 (de) 1970-05-14 1971-12-02 Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen Verfahren zur Herstellung von 5,6-gamma-Pyridonderivaten
CH625521A5 (fr) 1976-10-15 1981-09-30 Sandoz Ag
US5116840A (en) 1985-06-13 1992-05-26 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5834463A (en) 1994-04-29 1998-11-10 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
AU5844896A (en) 1995-06-01 1996-12-18 Takeda Chemical Industries Ltd. Tricyclic diazepines useful as gnrh receptor antagonists
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
FR2792937B1 (fr) 1999-04-27 2001-08-10 Cemaf NOUVEAUX DERIVES DE PYRROLO-(3,4-b) QUINOLEINE, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION A TITRE DE MEDICAMENT
UA72611C2 (uk) 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
JP4484517B2 (ja) 2001-11-14 2010-06-16 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ホスホジエステラーゼ阻害剤として有用な置換された四環式ピロロキノロン誘導体

Also Published As

Publication number Publication date
DK1534707T3 (da) 2008-03-25
AU2010202008A1 (en) 2010-06-10
PT1534707E (pt) 2007-12-19
CA2490239C (fr) 2011-05-24
DE60317684T4 (de) 2011-06-22
JP4916662B2 (ja) 2012-04-18
WO2004000842A1 (fr) 2003-12-31
ES2297217T3 (es) 2008-05-01
SI1534707T1 (sl) 2008-04-30
EP1534707B1 (fr) 2007-11-21
CN100349893C (zh) 2007-11-21
EP1534707B9 (fr) 2008-11-26
CA2490239A1 (fr) 2003-12-31
EP1534707A1 (fr) 2005-06-01
US20040006079A1 (en) 2004-01-08
DE60317684T2 (de) 2008-10-30
US6800625B2 (en) 2004-10-05
CN1675210A (zh) 2005-09-28
DE60317684D1 (de) 2008-01-03
JP2005532370A (ja) 2005-10-27
AU2003243640A1 (en) 2004-01-06
CY1107196T1 (el) 2012-11-21

Similar Documents

Publication Publication Date Title
HK1093503A1 (en) Pyrido 2, 1-a-isoquinoline derivatives as ddp-IV inhibitors
NO2017014I1 (no) 6-acetyl-8-cyclopentyl-5-metyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-on
NO20054330D0 (no) 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
NO20054331D0 (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
NO20023828L (no) Pyrimidin-4-on derivater som LDL-PLA2 inhibitorer
DK1289985T3 (da) Beta-carbolinderivater anvendelige som phosphodiesteraseinhibitorer
NO20053600D0 (no) Pyrazolo (3,4-b)pyridinforbindelser og anvendelse derav som fosfodiesterase inhibitorer.
DK1381363T3 (da) Imidazo[1,2-a]pyridinderivater som mGluR5-antagonister
NO20043174L (no) Pyrido[2,1-a]isokinolinderivater som DPP-IV inhibitorer
NO20053955D0 (no) Pyrazolo [1,5-A] pyrimidinderivater
NO20021695L (no) 5-(2-substituerte-5-heterocykylsulfonylpyrid-3-yl)-dihydro- pyrazolo[4,3-D]pyrimidin-7-oner som fosfodiesterase inhibitorer
DK1697356T3 (da) Pyrido[2,3-d]pyrimidin-2,4-diaminer som PDE 2-inhibitorer
DK1944305T3 (da) Quinolinderivater som phosphodiesteraseinhibitorer
ATE360632T1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate
DK1644376T3 (da) Pyrrolo 3,4-C pyrazol-derivater, der er aktive som kinase-inhibitorer
DK1534707T3 (da) Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer
HK1054034A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors.
DK1226143T3 (da) Imidazopyridinderivater som phosphodiesterase VII-inhibitorer
AU2003273989A1 (en) Quinazolinone derivatives useful as anti-hyperalgesic agents
AU2003250475A1 (en) 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
DK1948661T3 (da) Pyrazolo[4,3-D]pyrimidin-5-YL)-derivat anvendt som PDE5-inhibitorer
NO20055518D0 (no) 5-hydroksyindoler med N-oksidgrupper, anvendelse derav som fosfodiesterase 4-inhibitor
DK1560830T3 (da) Derivater af [6,7-dihydro-5H-imidazo[1,2-A]imidazol-3-sulfonylamino]propionamid og anvendelse deraf som inhibitorer af interaktionen mellem CAM'er og leukointegriner
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer